3.11
0.13 (4.36%)
| Previous Close | 2.98 |
| Open | 3.00 |
| Volume | 299,558 |
| Avg. Volume (3M) | 834,081 |
| Market Cap | 105,333,520 |
| Price / Sales | 0.130 |
| Price / Book | 0.480 |
| 52 Weeks Range | |
| Earnings Date | 13 May 2025 - 19 May 2025 |
| Profit Margin | -25.40% |
| Operating Margin (TTM) | -12.75% |
| Diluted EPS (TTM) | -4.61 |
| Quarterly Revenue Growth (YOY) | -11.50% |
| Total Debt/Equity (MRQ) | 263.27% |
| Current Ratio (MRQ) | 1.57 |
| Operating Cash Flow (TTM) | -4.76 M |
| Levered Free Cash Flow (TTM) | 19.30 M |
| Return on Assets (TTM) | -4.78% |
| Return on Equity (TTM) | -56.93% |
Market Trend
| Short Term | Medium Term | ||
| Industry | Diagnostics & Research (US) | Bearish | Bearish |
| Diagnostics & Research (Global) | Bearish | Bearish | |
| Stock | Inotiv, Inc. | Mixed | Bearish |
AIStockmoo Score
| Analyst Consensus | -2.0 |
| Insider Activity | -3.0 |
| Price Volatility | -2.0 |
| Technical Moving Averages | 2.5 |
| Technical Oscillators | -2.0 |
| Average | -1.30 |
|
Inotiv Inc is a pharmaceutical development company specializing in nonclinical and analytical drug discovery, development services to the pharmaceutical, chemical, and medical device industries. It operates in two segments; Discovery and Safety Assessment (DSA) and Research Models and Services (RMS). Through the DSA segment, the company supports the discovery, nonclinical development, and clinical development needs of researchers and clinicians for small molecule drug candidates, biotherapeutics, and biomedical devices. Through the RMS segment, the company offers access to a wide range of small and large research models for basic research, drug discovery, development, and specialized models for specific diseases and therapeutic areas. The company earns maximum revenue from RMS Segment. |
|
| Sector | Healthcare |
| Industry | Diagnostics & Research |
| Investment Style | Small Value |
| % Held by Insiders | 11.66% |
| % Held by Institutions | 26.32% |
Ownership
| Name | Date | Shares Held |
|---|---|---|
| Kpp Advisory Services Llc | 31 Dec 2024 | 275,267 |
No data within this time range.
No data within this time range.
| Date | Type | Details |
|---|---|---|
| 06 Apr 2025 | Announcement | Sea Pharmaceuticals Announces Strategic Relationship to Advance Treatments For Patients with CNS Disorders |
| 05 Feb 2025 | Announcement | Inotiv Reports First Quarter Financial Results for Fiscal 2025 and Provides Business Update |
| 22 Jan 2025 | Announcement | Inotiv, Inc. to Report Fiscal 2025 First Quarter Financial Results and Host Conference Call on Wednesday, February 5, 2025 |
The support, resistance and trendline levels presented has been generated by an artificial intelligence (AI) model and should be interpreted with caution.
Portfolio
| Realized Profit | - |
| Unrealized Profit | - |
| Dividend Received 2025 | - |
| Total Profit | - |
| Avg. Return | - |
| Quantity (Buy) | - |
| Avg. Price (Buy) | - |
| Quantity (Sold) | - |
| Avg. Price (Sold) | - |